HCW Biologics Inc (HCWB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, HCW Biologics Inc (HCWB) has a cash flow conversion efficiency ratio of -1.214x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.36 Million) by net assets ($2.76 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See HCW Biologics Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
HCW Biologics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how HCW Biologics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
HCW Biologics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HCW Biologics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Magle Chemoswed Holding Ab
ST:MAGLE
|
-0.006x |
|
Easson Holdings Ltd
PA:MLEAS
|
N/A |
|
CrownHaitai Holdings Co Ltd Preference Shares
KO:005745
|
0.026x |
|
AGM Group Holdings Inc Class A
NASDAQ:AGMH
|
-0.078x |
|
Galeo Concept SA
PA:MLGAL
|
N/A |
|
Ace Integrated Solutions Limited
NSE:ACEINTEG
|
0.021x |
|
TECIL Chemicals and Hydro Power Limited
NSE:TECILCHEM
|
N/A |
|
Accsys Technologies PLC
LSE:AXS
|
0.068x |
Annual Cash Flow Conversion Efficiency for HCW Biologics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of HCW Biologics Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see HCW Biologics Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.76 Million | $-13.39 Million | -4.844x | -330.49% |
| 2024-12-31 | $-6.77 Million | $-14.23 Million | 2.101x | +225.65% |
| 2023-12-31 | $13.46 Million | $-22.51 Million | -1.672x | -502.70% |
| 2022-12-31 | $37.43 Million | $-10.39 Million | -0.277x | -29.43% |
| 2021-12-31 | $51.19 Million | $-10.98 Million | -0.214x | +70.41% |
| 2020-12-31 | $14.40 Million | $-10.43 Million | -0.725x | +3.61% |
| 2019-12-31 | $9.00 Million | $-6.77 Million | -0.752x | -- |
About HCW Biologics Inc
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and … Read more